| Source: |
| Type: |
| Normal cells grow and divide in a regulated manner through the cell cycle, which consists of phases (G1, S, G2, and M). Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. This can result from mutations in genes that control the cell cycle, such as oncogenes (which promote cell division) and tumor suppressor genes (which inhibit cell division). |
| 1563- | Api, | MET, | Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells |
| - | in-vitro, | Nor, | HDFa | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | NA, | NA |
| 2634- | Api, | Apigenin induces both intrinsic and extrinsic pathways of apoptosis in human colon carcinoma HCT-116 cells |
| - | in-vitro, | CRC, | HCT116 |
| 2585- | Api, | Apigenin inhibits the proliferation of adenoid cystic carcinoma via suppression of glucose transporter-1 |
| - | in-vitro, | ACC, | NA |
| 2316- | Api, | The interaction between apigenin and PKM2 restrains progression of colorectal cancer |
| - | in-vitro, | CRC, | LS174T | - | in-vitro, | CRC, | HCT8 | - | in-vivo, | CRC, | NA |
| 1024- | Api, | CUR, | Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects |
| - | vitro+vivo, | Melanoma, | A375 | - | in-vitro, | Melanoma, | A2058 | - | in-vitro, | Melanoma, | RPMI-7951 |
| - | in-vitro, | BC, | BT474 |
| 179- | Api, | Apigenin induces caspase-dependent apoptosis by inhibiting signal transducer and activator of transcription 3 signaling in HER2-overexpressing SKBR3 breast cancer cells |
| - | in-vitro, | BC, | SkBr3 |
| 1147- | ART/DHA, | Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1 |
| - | vitro+vivo, | Ovarian, | HO-8910 | - | vitro+vivo, | Nor, | HUVECs |
| 5380- | ART/DHA, | Artemisinin and Its Derivatives as Potential Anticancer Agents |
| - | Review, | Var, | NA |
| 5135- | ART/DHA, | Dihydroartemisinin Inhibits mTORC1 Signaling by Activating the AMPK Pathway in Rhabdomyosarcoma Tumor Cells |
| - | vitro+vivo, | Var, | NA |
| 5130- | ART/DHA, | Dihydroartemisinin Induces Apoptosis in Human Bladder Cancer Cell Lines Through Reactive Oxygen Species, Mitochondrial Membrane Potential, and Cytochrome C Pathway |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 570- | ART/DHA, | Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling |
| - | vitro+vivo, | NSCLC, | A549 | - | vitro+vivo, | NSCLC, | H1299 |
| 561- | ART/DHA, | Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo |
| - | in-vivo, | NA, | NA |
| 2576- | ART/DHA, | AL, | The Synergistic Anticancer Effect of Artesunate Combined with Allicin in Osteosarcoma Cell Line in Vitro and in Vivo |
| - | in-vitro, | OS, | MG63 | - | in-vivo, | NA, | NA |
| 2582- | ART/DHA, | 5-ALA, | Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal Cancer Activity |
| - | in-vivo, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT116 |
| 5395- | Ash, | Withaferin A Targets Heat Shock Protein 90 in Pancreatic Cancer Cells |
| - | vitro+vivo, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 |
| 5398- | Ash, | Withaferin-A inhibits colorectal cancer growth and metastasis by targeting the HSP90/HIF-1α/EMT axis |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| 1356- | Ash, | Withaferin A induces apoptosis by ROS-dependent mitochondrial dysfunction in human colorectal cancer cells |
| - | in-vitro, | CRC, | HCT116 |
| 1363- | Ash, | doxoR, | Withaferin A Synergizes the Therapeutic Effect of Doxorubicin through ROS-Mediated Autophagy in Ovarian Cancer |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | CaOV3 | - | in-vivo, | NA, | NA |
| 5171- | Ash, | The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry" |
| - | vitro+vivo, | Pca, | LNCaP | - | vitro+vivo, | Pca, | PC3 |
| 5173- | Ash, | 2DG, | Withaferin A inhibits lysosomal activity to block autophagic flux and induces apoptosis via energetic impairment in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | T47D |
| 4660- | Ash, | Withaferin A Alone and in Combination with Cisplatin Suppresses Growth and Metastasis of Ovarian Cancer by Targeting Putative Cancer Stem Cells |
| - | in-vitro, | Ovarian, | NA |
| 5384- | AsP, | MEL, | Synergistic Anticancer Effect of Melatonin and Ascorbyl Palmitate Nanoformulation: A Promising Combination for Cancer Therapy |
| - | in-vivo, | Var, | NA |
| 5387- | AsP, | PacT, | Ascorbyl palmitate-incorporated paclitaxel-loaded composite nanoparticles for synergistic anti-tumoral therapy |
| - | in-vivo, | Melanoma, | B16-F10 |
| 4814- | ASTX, | Chemopreventive and therapeutic efficacy of astaxanthin against cancer: A comprehensive review |
| - | Review, | Var, | NA |
| 4807- | ASTX, | An overview of the anticancer activity of astaxanthin and the associated cellular and molecular mechanisms |
| - | Review, | Var, | NA |
| 4806- | ASTX, | Astaxanthin's Impact on Colorectal Cancer: Examining Apoptosis, Antioxidant Enzymes, and Gene Expression |
| - | in-vitro, | CRC, | HCT116 |
| 5421- | ASTX, | Astaxanthin Inhibits PC-3 Xenograft Prostate Tumor Growth in Nude Mice |
| - | in-vivo, | Pca, | NA |
| 5451- | ATV, | In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | A172 |
| 5449- | ATV, | Pleiotropic effects of statins: A focus on cancer |
| - | NA, | Var, | NA |
| 4986- | ATV, | Dipy, | The combination of statins and dipyridamole is effective preclinically in AML, MM, and breast cancer |
| - | Review, | Var, | NA |
| 5363- | AV, | Exploring the mechanism of aloe-emodin in the treatment of liver cancer through network pharmacology and cell experiments |
| - | Study, | HCC, | NA |
| 874- | B-Gluc, | Potential promising anticancer applications of β-glucans: a review |
| - | Review, | NA, | NA |
| 5249- | Ba, | BA, | Baicalein and baicalin in cancer therapy: Multifaceted mechanisms, preclinical evidence, and translational challenges |
| - | Review, | Var, | NA |
| 5251- | Ba, | The Fascinating Effects of Baicalein on Cancer: A Review |
| - | Review, | Var, | NA |
| 1288- | Ba, | The Traditional Chinese Medicine Baicalein Potently Inhibits Gastric Cancer Cells |
| - | in-vitro, | GC, | SGC-7901 |
| 1521- | Ba, | Baicalein induces apoptosis via ROS-dependent activation of caspases in human bladder cancer 5637 cells |
| - | in-vitro, | Bladder, | 5637 |
| 1520- | Ba, | Baicalein Induces G2/M Cell Cycle Arrest Associated with ROS Generation and CHK2 Activation in Highly Invasive Human Ovarian Cancer Cells |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | TOV-21G |
| 2477- | Ba, | Baicalein induces apoptosis via a mitochondrial-dependent caspase activation pathway in T24 bladder cancer cells |
| - | in-vitro, | CRC, | T24/HTB-9 |
| 2476- | Ba, | Baicalein Induces Caspase-dependent Apoptosis Associated with the Generation of ROS and the Activation of AMPK in Human Lung Carcinoma A549 Cells |
| - | in-vitro, | Lung, | A549 |
| 2603- | Ba, | Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 2618- | Ba, | Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer |
| - | in-vitro, | Lung, | H1299 | - | in-vivo, | Lung, | A549 |
| 2298- | Ba, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2291- | Ba, | BA, | Baicalein and Baicalin Promote Melanoma Apoptosis and Senescence via Metabolic Inhibition |
| - | in-vitro, | Melanoma, | SK-MEL-28 | - | in-vitro, | Melanoma, | A375 |
| 5541- | BBM, | Berbamine Suppresses the Growth of Gastric Cancer Cells by Inactivating the BRD4/c-MYC Signaling Pathway |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | BGC-823 |
| 5542- | BBM, | Pharmacological profiling of a berbamine derivative for lymphoma treatment |
| - | vitro+vivo, | lymphoma, | NA |
| 5543- | BBM, | Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo |
| - | in-vivo, | Lung, | B16-F10 | - | vitro+vivo, | Lung, | A549 | - | in-vitro, | BC, | MDA-MB-231 |
| 5555- | BBM, | Berbamine inhibits cell proliferation and invasion by increasing FTO expression in renal cell carcinoma cells |
| - | vitro+vivo, | RCC, | NA |
| 5549- | BBM, | Synergistic Anticancer Effect of a Combination of Berbamine and Arcyriaflavin A against Glioblastoma Stem-like Cells |
| - | in-vitro, | GBM, | NA |
| 1397- | BBR, | Chemo, | Effects of Coptis extract combined with chemotherapeutic agents on ROS production, multidrug resistance, and cell growth in A549 human lung cancer cells |
| - | in-vitro, | Lung, | A549 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:323 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid